Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS

Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS (PPMS) (H øjsgaard Chow et al., 2021). In order to further analyze the immunological treatment response we investigated the systemic and intrathecal immunological effects of dimethyl fumarate (DMF) treatment in 50 patients with PPMS who participated in a 48-week randomized controlled trial with dimethyl fuma rate vs placebo.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Source Type: research